FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1278-1280 March 25, 2004 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Shulenin, S. PubMed Citation

After the first observation of surfactant deficiency in infants who were dying of the respiratory distress syndrome (also known as hyaline membrane disease), a series of investigations led to effective therapies, including surfactant therapy given at birth. These therapies, in turn, have led to a dramatic decrease in mortality associated with the respiratory distress syndrome, from nearly 100 percent to less than 10 percent. Most infants who die from the syndrome are preterm. Surfactant therapy is usually not required beyond the first day of life, because the turnover of surfactant is slow in newborns, and the rapid differentiation of alveolar . . . [Full Text of this Article]

Source Information

From the Biocenter Oulu and the Department of Pediatrics, University of Oulu — both in Oulu, Finland.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.